Novo Nordisk CEO eyes longevity, aesthetics markets

Novo Nordisk CEO Eyes Longevity and Aesthetics Beyond Weight Loss

Novo Nordisk CEO Mike Doustdar said Sunday that the Danish drugmaker’s blockbuster obesity medications could eventually carry the company into longevity research and aesthetic medicine, broadening the company’s ambitions well beyond its core diabetes and weight-loss franchise.

Speaking at the American Diabetes Association’s 86th Scientific Sessions in New Orleans, Doustdar said the company must follow where patient demand leads. “We must be dedicated to understanding our patients’ needs,” he said during an interview at the conference, which runs June 5–8.bloomberglaw

New Pipeline Data Bolsters Strategy

The CEO’s remarks came as Novo Nordisk presented a wave of clinical data at the ADA meeting, including results for its investigational drug zenagamtide, also known as amycretin. The dual GLP-1 and amylin receptor agonist showed weight loss of up to 14.6% at the highest dose tested in a phase 2 trial of adults with type 2 diabetes over 36 weeks, alongside A1C reductions of up to 1.71 percentage points. Up to 89.1% of participants achieved A1C levels below 7%. The company said it plans to advance zenagamtide into phase 3 trials in the second half of 2026.prnewswire

The amycretin results represent a potential pipeline recovery for Novo Nordisk, which saw its shares decline after earlier setbacks and a forecast of 5 to 13% sales decline at constant exchange rates for 2026. The drug showed no apparent weight-loss plateau at higher doses, a detail investors had been watching closely.yahoo

Wegovy’s Expanding Reach

Novo Nordisk also presented new analyses of Wegovy data spanning its cardiometabolic clinical trial programs, reinforcing the drug’s benefits beyond weight reduction. Those presentations build on the landmark SELECT trial, which showed semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established heart disease.novonordisk

The company has also been generating data on an oral formulation of Wegovy, which showed average weight loss of 17% in the OASIS 4 trial, with early responders achieving up to 21.6%.biospace

A Broader Vision

Doustdar’s comments on longevity and aesthetics signal an attempt to reframe Novo Nordisk’s GLP-1 franchise as a platform for broader health applications. The company already has a deep pipeline featuring CagriSema, which showed 14.2% weight loss in people with type 2 diabetes in its REIMAGINE 2 phase 3 trial, and is preparing regulatory filings for that drug as well.novonordisk

Whether the obesity drug giant can translate its clinical heft into adjacent markets like anti-aging and cosmetic medicine remains to be seen — but with multiple next-generation drugs advancing and its CEO publicly staking out new territory, Novo Nordisk is clearly betting that its GLP-1 story is far from over.